Cargando…

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data

SIMPLE SUMMARY: Patients near the end of life often receive aggressive care, which may be of low value. For patients with advanced cancers, it is standard clinical practice to estimate the prognosis to inform treatment decisions and improve end-of-life care. However, clinical estimates of prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuechen, Kerrigan, Kathleen, Puri, Sonam, Shen, Jincheng, Akerley, Wallace, Haaland, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833771/ https://www.ncbi.nlm.nih.gov/pubmed/35158958 http://dx.doi.org/10.3390/cancers14030690

Ejemplares similares

A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern
por: Kerrigan, Kathleen, et al.
Publicado: (2022)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study
por: Thronicke, Anja, et al.
Publicado: (2020)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence
por: Jovanoski, Nick, et al.
Publicado: (2023)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

Nomogram-based parameters to predict overall survival in a real-world advanced cancer population undergoing palliative care
por: Zhao, Weiwei, et al.
Publicado: (2019)

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents
por: Hafron, Jason M., et al.
Publicado: (2022)

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
por: Bowes, Kathleen, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival
por: Roszik, Jason, et al.
Publicado: (2022)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
por: Catarino, Raquel, et al.
Publicado: (2012)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

LMD-15. Beyond cytologY - A single institution experience using CNSide(TM) for diagnosing and monitoring treatment response in Non-Small Cell Lung Cancer patients with Leptomeningeal Carcinomatosis (LMC)
por: Akerley, Wallace, et al.
Publicado: (2021)

Real Women, Real Leaders: Surviving and Succeeding in the Business World
por: Hurley, Kathleen
Publicado: (2015)

Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma
por: Deng, Xiangyang, et al.
Publicado: (2020)

Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
por: Qureshi, Samia, et al.
Publicado: (2022)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
por: Ton, Thanh G.N., et al.
Publicado: (2022)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis
por: Sun, Wenzheng, et al.
Publicado: (2018)

Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC
por: Shepherd, Annemarie F., et al.
Publicado: (2021)

Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC
por: Cronemberger, Eduardo, et al.
Publicado: (2020)

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study
por: Hong, Xinyi, et al.
Publicado: (2023)

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis
por: Dong, Qiu, et al.
Publicado: (2021)

Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India
por: M, Srikanth Goud, et al.
Publicado: (2022)

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
por: Kartolo, Adi, et al.
Publicado: (2022)

Real‐world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
por: Lasiter, Laura, et al.
Publicado: (2021)

Nomogram for predicting overall survival in patients with large (>5 cm) hepatocellular carcinoma based on real-world practice
por: Kim, Nalee, et al.
Publicado: (2023)

Identification of a five-gene signature in association with overall survival for hepatocellular carcinoma
por: Yang, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rkrijju0bsde5nm606fp0hcsvd